JP2024511695A5 - - Google Patents

Info

Publication number
JP2024511695A5
JP2024511695A5 JP2023547047A JP2023547047A JP2024511695A5 JP 2024511695 A5 JP2024511695 A5 JP 2024511695A5 JP 2023547047 A JP2023547047 A JP 2023547047A JP 2023547047 A JP2023547047 A JP 2023547047A JP 2024511695 A5 JP2024511695 A5 JP 2024511695A5
Authority
JP
Japan
Prior art keywords
ophthalmic composition
topical ophthalmic
approximately
composition according
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023547047A
Other languages
English (en)
Japanese (ja)
Other versions
JP7749020B2 (ja
JP2024511695A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014811 external-priority patent/WO2022169788A1/en
Publication of JP2024511695A publication Critical patent/JP2024511695A/ja
Publication of JP2024511695A5 publication Critical patent/JP2024511695A5/ja
Priority to JP2025157079A priority Critical patent/JP2025176201A/ja
Application granted granted Critical
Publication of JP7749020B2 publication Critical patent/JP7749020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023547047A 2021-02-03 2022-02-02 局所眼科用組成物 Active JP7749020B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025157079A JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163145091P 2021-02-03 2021-02-03
US63/145,091 2021-02-03
PCT/US2022/014811 WO2022169788A1 (en) 2021-02-03 2022-02-02 Topical ophthalmological compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025157079A Division JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Publications (3)

Publication Number Publication Date
JP2024511695A JP2024511695A (ja) 2024-03-15
JP2024511695A5 true JP2024511695A5 (cg-RX-API-DMAC10.html) 2025-04-21
JP7749020B2 JP7749020B2 (ja) 2025-10-03

Family

ID=82741579

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547047A Active JP7749020B2 (ja) 2021-02-03 2022-02-02 局所眼科用組成物
JP2025157079A Pending JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025157079A Pending JP2025176201A (ja) 2021-02-03 2025-09-22 局所眼科用組成物

Country Status (8)

Country Link
US (3) US12070501B1 (cg-RX-API-DMAC10.html)
EP (1) EP4288151A4 (cg-RX-API-DMAC10.html)
JP (2) JP7749020B2 (cg-RX-API-DMAC10.html)
KR (1) KR20230142548A (cg-RX-API-DMAC10.html)
AU (1) AU2022217160A1 (cg-RX-API-DMAC10.html)
CA (1) CA3206612A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023009091A (cg-RX-API-DMAC10.html)
WO (1) WO2022169788A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL268457B (en) * 2019-08-04 2022-05-01 Omega 3 Galilee Ltd Oil- suspension of edible solids and methods of preparing the same
US11191751B1 (en) * 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions
WO2025034554A1 (en) * 2023-08-04 2025-02-13 Ads Therapeutics Llc Compositions and methods for delivery of ophthalmological actives
WO2025131038A1 (en) * 2023-12-21 2025-06-26 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2025259674A1 (en) * 2024-06-11 2025-12-18 Ads Therapeutics Llc Compositions and methods for delivery of pharmaceutical actives
WO2026003129A1 (en) * 2024-06-26 2026-01-02 Novaliq Gmbh Stabilization of (r)-ruxolitinib

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
DE10030378A1 (de) 2000-06-21 2002-03-14 Audit Inst For Medical Service Neue pharmazeutische Zusammensetzung zur topischen Anwendung von wasserunlöslichen und/oder schwer wasserlöslichen Wirkstoffen
CN101049287A (zh) 2006-04-07 2007-10-10 财团法人长庚纪念医院 抑制近视度数增加的低浓度阿托平眼药剂及其制造方法
US20070254914A1 (en) 2006-05-01 2007-11-01 Non-Profit Organization Chang Gung Memorial Hospital Low-concentration atropine solution for preventing myopia progression and preparing method thereof
US20100323978A1 (en) * 2009-06-22 2010-12-23 Calvin Hanna Non-aqueous oil delivery system for ophthalmic drugs
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
WO2012161655A1 (en) 2011-05-23 2012-11-29 Singapore Health Services Pte Ltd Composition and/or method for reducing and/or preventing myopia progression comprising atropine
CN102526051A (zh) * 2012-03-09 2012-07-04 哈尔滨医科大学 一种治疗真菌性角膜炎的眼药膏
EP2895144B1 (en) 2012-09-12 2017-01-11 Novaliq GmbH Semifluorinated alkane compositions
MX363182B (es) * 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP2783703A1 (en) 2013-03-25 2014-10-01 B. Braun Melsungen AG Semifluorocarbon compound containing contrast agent
US9421199B2 (en) * 2014-06-24 2016-08-23 Sydnexis, Inc. Ophthalmic composition
WO2016172712A2 (en) * 2015-04-23 2016-10-27 Sydnexis, Inc. Ophthalmic composition
KR20170120161A (ko) * 2015-03-05 2017-10-30 알러간, 인코포레이티드 안과용 약물 전달을 위한 자가-유화 약물 전달 시스템(sedds)
CN109803650A (zh) 2016-09-28 2019-05-24 诺瓦利克有限责任公司 包含大麻素受体结合配体的组合物
WO2018064354A1 (en) 2016-09-28 2018-04-05 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2018114557A1 (en) 2016-12-22 2018-06-28 Novaliq Gmbh Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
EP3585386A4 (en) 2017-02-21 2020-12-30 Singapore Health Services PTE Ltd COMPOSITION AND PROCESS FOR PREVENTING OR DELAYING THE ONCE OF MYOPIA INCLUDING ATROPINE
EP3638643B1 (en) 2017-06-12 2023-01-18 Novaliq GmbH Process for the preparation of semifluorinated alkanes using grignard reagents
JP7814839B2 (ja) 2017-09-27 2026-02-17 ノバリック ゲーエムベーハー 眼疾患の治療に使用するためのラタノプロストを含む眼科用組成物
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
CA3112031A1 (en) 2018-10-12 2020-04-16 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
CN113518619A (zh) 2019-01-21 2021-10-19 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的药物组合物
AU2020216470B2 (en) * 2019-02-01 2023-05-04 Alcon Inc. Compounds, compositions and methods for treatment of myopia
US11191751B1 (en) 2020-10-08 2021-12-07 Ads Therapeutics Llc Topical ophthalmological atropine free base compositions

Similar Documents

Publication Publication Date Title
JP6869336B2 (ja) シクロスポリンを含む眼科用組成物
JP4463681B2 (ja) 眼内使用のための非ポリマー親油性薬学的インプラント組成物
JP6352366B2 (ja) 半フッ素化アルカン組成物
JP6670283B2 (ja) タペンタドールを含む半固形の水性医薬組成物
JP5654444B2 (ja) 望ましい生物学的利用能を有する薬学的組成物
JP5654987B2 (ja) 日光角化症の処置のための局所用組成物
RU2015131700A (ru) Фармацевтические композиции, включающие производное камптотецина
CN101043884A (zh) 用于治疗眼部疾病和病症的组合物和方法
CN101808638A (zh) 抗真菌组合物
TW200934530A (en) Topical composition
RU2006115596A (ru) Твердые дозированные формы, включающие фибрат и статин
JP7506603B2 (ja) 局所用組成物
CN104602670A (zh) 含有ω-3 脂肪酸的眼用组合物
CN1909891A (zh) 药用组合物的微乳液
JPWO2017110874A1 (ja) 涙液油層安定化剤およびこれを含有する点眼剤
JP2024544415A5 (cg-RX-API-DMAC10.html)
JP2018505905A (ja) 局所医薬製剤
AU2018215386B2 (en) Topical composition
TW200930381A (en) Compositions and methods for the treatment of bladder cancer
WO1990013290A1 (fr) Composition pharmaceutique a base de paracetamol
JP2024505517A5 (cg-RX-API-DMAC10.html)
RU2008105323A (ru) Консервирующая композиция для офтальмологического применения
ES2460967T3 (es) Método para la prevención de la degradación de una sustancia térmicamente inestable
ES2731151T3 (es) Composiciones oftálmicas basadas en ácidos poliinsaturados y triacilgliceroles
JPWO2022138826A5 (cg-RX-API-DMAC10.html)